Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 7/20 | 0.58 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | NT5E | P21589 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL723979 | 0.91 | ADORA2A (0.62) | ADORA2AADORA2BLMNANT5EHIF1A | |
| SCHEMBL725702 | 0.89 | ADORA2A (0.63) | ADORA2AADORA2BLMNANT5EHIF1A | |
| SCHEMBL3422427 | 0.84 | ADORA2A (0.66) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL5034102 | 0.83 | ADORA3 (0.63) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL5032143 | 0.83 | ADORA3 (0.62) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL22567702 | 0.83 | ADORA2A (0.56) | ADORA2AADORA2BLMNANT5EHIF1A | |
| SCHEMBL465954 | 0.82 | ADORA2A (0.56) | ADORA2AADORA2BLMNANT5EHIF1A | |
| SCHEMBL725880 | 0.82 | ADORA2A (0.57) | ADORA2AADORA2BLMNANT5EHIF1A | |
| SCHEMBL271079 | 0.82 | ADORA2A (0.61) | ADORA2AADORA2BLMNANT5EHIF1A | |
| SCHEMBL1382431 | 0.82 | ADORA2A (0.57) | ADORA2AADORA2BLMNANT5EHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010065959-A1 | METHOD OF PREPARING ADENOSINE-RESISTANT ANTI-TUMOR T LYMPHOCYTES FOR ADOPTIVE IMMUNOTHERAPY | NORTHEASTERN UNIVERSITY (US) | 2010-06-10 | — | — | WO | disclosed |
| EP-2099360-A2 | MYOCARDIAL PERFUSION IMAGING | CV Therapeutics Inc. (US) | 2009-09-16 | — | — | EP | disclosed |
| EP-2056834-A1 | METHODS AND COMPOSITIONS FOR INCREASING PATIENT TOLERABILITY DURING MYOCARDIAL IMAGING METHODS | CV THERAPEUTICS, INC. (US) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008086096-A2 | MYOCARDIAL PERFUSION IMAGING | CV THERAPEUTICS, INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008028140-A1 | METHODS AND COMPOSITIONS FOR INCREASING PATIENT TOLERABILITY DURING MYOCARDIAL IMAGING METHODS | CV THERAPEUTICS, INC. (US) | 2008-03-06 | — | — | WO | disclosed |
| EP-1189916-A2 | N-PYRAZOLE A 2A RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2002-03-27 | — | — | EP | disclosed |
| WO-2000078779-A2 | N-PYRAZOLE A2A RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2000-12-28 | — | — | WO | disclosed |